Compare Li Auto Inc (LI) vs Pfizer Inc (PFE) Price & Performance

Li Auto (LI) trades at $10.90, down 0.82% and near 52-week lows amid delivery moderation concerns. The stock shows bearish technical signals with negative moving averages and neutral oscillators. Fundamentally, revenue declined to $112.31B in 2025 with net income of $1.12B, though recent quarterly earnings missed expectations. Analyst sentiment is mixed with 44% buy ratings but a consensus price target of $15.18, suggesting 39% upside potential from current levels.

The outlook remains challenging with competitive pressures and cash flow concerns, but the company's strong balance sheet ($112.81B cash) provides cushion. New model launches (Li i9, MEGA) and global expansion could drive recovery, though execution risks and China's auto market weakness pose headwinds. The stock appears undervalued on P/S (0.73) and EV/EBITDA (1.72) metrics relative to growth potential.

Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.

The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.